Bernard A, Viau C, Lauwerys R
Arch Toxicol. 1983 May;53(1):49-57. doi: 10.1007/BF01460001.
The renal handling of human beta 2-microglobulin (beta 2-m) was investigated in normal rat and in rat with cadmium-induced renal damage. Cadmium was administered either in drinking water at a concentration of 100 ppm for up to 16 months or by i.p. injection of 1 mg Cd/kg, five times a week for up to 4 months. When renal dysfunction has developed, namely after 2 and 10 months of the i.p. and oral treatment respectively, unlabelled human beta 2-m was injected intravenously and its disappearance in serum and its urinary excretion were studied by means of a sensitive immunoassay. In serum, the level of beta 2-m drops by about 90% during the 10 first min, then declines more slowly with a half life around 20 min. Serum disappearance curves of beta 2-m in normal and cadmium-treated rats did not differ markedly. The amount of beta 2-m recovered in urine during the 4 h following the injection averaged 0.03% of the injected dose in normal rats. It increased on the average to 10% in rats treated i.p. with 1 mg Cd/kg for 3 months. However, in rats given 100 ppm Cd per os for 10 months, this amount averaged only 0.14%. A similar value was observed 5 months later, although at that stage, the critical level of cadmium in kidney cortex had been reached for 6-7 months. These data which were in accordance with the disturbances of the other renal parameters measured in cadmium-treated rats indicate that: 1) human beta 2-m is reabsorbed by rat kidney at a similar rate as by human kidney; 2) if the occurrence of cadmium tubulopathy is concomitant with the saturation of cadmium-binding sites in kidney, its severity depends greatly on the rate at which cadmium reaches the saturated kidneys.
在正常大鼠和镉诱导的肾损伤大鼠中研究了人β2-微球蛋白(β2-m)的肾脏处理情况。镉通过浓度为100 ppm的饮用水给药,持续16个月,或通过腹腔注射1 mg Cd/kg,每周5次,持续4个月。当肾功能出现障碍时,即分别在腹腔注射和口服治疗2个月和10个月后,静脉注射未标记的人β2-m,并通过灵敏的免疫测定法研究其在血清中的消失情况及其尿排泄情况。在血清中,β2-m的水平在最初10分钟内下降约90%,然后下降得更慢,半衰期约为20分钟。正常大鼠和镉处理大鼠中β2-m的血清消失曲线没有明显差异。注射后4小时内尿中回收的β2-m量在正常大鼠中平均为注射剂量的0.03%。在用1 mg Cd/kg腹腔注射治疗3个月的大鼠中,该量平均增加到10%。然而,在口服100 ppm Cd 10个月的大鼠中,该量平均仅为0.14%。5个月后观察到类似的值,尽管在那个阶段,肾皮质中的镉临界水平已经达到6-7个月。这些数据与在镉处理大鼠中测量的其他肾脏参数的紊乱情况一致,表明:1)人β2-m被大鼠肾脏重吸收的速率与人肾脏相似;2)如果镉肾小管病的发生与肾脏中镉结合位点的饱和同时发生,其严重程度很大程度上取决于镉到达饱和肾脏的速率。